| Literature DB >> 18081257 |
Ian Paterson1, Nicola M Gardner, Karine G Poullennec, Amy E Wright.
Abstract
By employing a diverted total synthesis strategy with late-stage intermediates, 10,11-dihydrodictyostatin ( 5) was prepared and evaluated in vitro for growth inhibition against a range of human cancer cell lines, including the NCI/ADR Taxol-resistant cell line. This novel dictyostatin analogue was found to retain potent antimitotic activity, with a comparable profile to discodermolide and Taxol, functioning by microtubule stabilization and G2/M arrest. These SAR studies provide further insight into the interaction between dictyostatin ( 1) and its tubulin target.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18081257 DOI: 10.1021/np070547s
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050